Personalised chemotherapy guidance for dogs could cut costs and extend disease control in relapsed canine lymphoma

ImpriMed’s retrospective analysis suggests that personalised chemotherapy guided by AI prediction models may improve disease control and reduce costs for dogs with relapsed lymphoma, highlighting the growing role of data-driven treatment planning in veterinary medicine and ongoing debates over retrospective evidence.

Personalised chemotherapy guidance may reduce the cost of controlling relapsed canine lymphoma, according to ImpriMed’s latest retrospective analysis. The company says matching treatment more closely to its prediction model was associated with longer disease control and a lower cost per day, a combination that could matter to veterinary oncologists and pet owners facing difficult decisions after relapse. For the animal-health sector, the finding adds to the case for data-driven treatment planning, but also raises the familiar question of how far retrospective evidence can support routine adoption.

ImpriMed, a Silicon Valley precision-medicine company, said the analysis was presented at the 2026 Veterinary Cancer Society annual conference in Minneapolis. It reviewed data from 60 dogs with relapsed B-cell lymphoma and compared outcomes with the company’s Personalized Prediction Profile, which uses live-cell testing and artificial intelligence to forecast drug response.

Dogs treated in closer alignment with the model’s recommendations recorded a median 49 days without progression, versus 21 days for the less closely matched group. The estimated cost per progression-free day was $117.09, against $188.53, a difference of 38%, although total treatment spend was higher because the better-matched group lived longer and remained on therapy longer.

The company says more than 340 hospitals now collaborate with it. Its broader pitch is that oncology decisions for dogs should weigh value as well as efficacy.